本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Can-Fite Biopharma Ltd

2.33
+0.17007.87%
盤後2.330.00000.00%19:54 EDT
成交量:15.50萬
成交額:35.41萬
市值:499.21萬
市盈率:-0.50
高:2.37
開:2.17
低:2.16
收:2.16
52周最高:13.40
52周最低:2.16
股本:214.25萬
流通股本:214.25萬
量比:0.95
換手率:7.23%
股息:- -
股息率:- -
每股收益(TTM):-4.6460
每股收益(LYR):-1,791.0249
淨資產收益率:-211.37%
總資產收益率:-77.12%
市淨率:1.03
市盈率(LYR):0.00

資料載入中...

2022/03/24

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/04

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/13

SEC問詢函

CORRESP [Cover] - Correspondence
2021/08/26

招股説明書

Can-Fite BioPharma Ltd.
2021/08/26

招股説明書

F-1 - Registration statement for certain foreign private issuers
2021/03/25

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/09

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/01/29

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/11/30

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/10/07

SEC問詢函

CORRESP [Cover] - Correspondence
2020/08/27

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/07/22

SEC問詢函

CORRESP [Cover] - Correspondence
2020/07/10

招股説明書

F-1 - Registration statement for certain foreign private issuers
2020/06/19

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/19

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/01

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/13

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]